BUSM professor receives Ellison Foundation grant to explore new Parkinson's disease target

NewsGuard 100/100 Score

Richard Myers, PhD, professor of neurology at Boston University School of Medicine (BUSM), was recently awarded $100,000 from the Ellison Foundation for research to further study a Parkinson's disease (PD) target.

The Myers research team will investigate the Cyclin G-associated kinase (GAK) gene and protein and why a deficiency of this gene increases the risk for developing Parkinson's disease (PD), a chronic and progressively worsening movement disorder that results from the malfunction and death of neurons. Currently, there is no cure for PD and the cause is unknown.

Myers seeks to define what versions of GAK are in the human brain, how they function and how certain variations could protect from PD. GAK is critical for a process that is essential for normal function and brain activity.

"We are seeking to understand how and why this gene has such a large impact on PD and to identify the mechanism by which the deficiency leads to the death of nerve cells in the brain," Myers, who is the director of the Genome Science Institute and the Aubrey Milunsky Chair in Human Genetics, said. "We have evidence that increasing the levels of this gene, or the protein it makes, may decrease or prevent the cell death seen in PD, and we will explore whether this may be a new avenue for treatment of PD."

Myers' interests focus on genetic research methods for the investigation of adult onset diseases, such as PD, Huntington's disease, obesity and more. His lab has been studying the genetics of PD for more than twenty years and has participated in a wide range of investigations for this disease.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals pivotal insights into the progression of Parkinson's disease